^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Archexin (WGI-0201)

    i
    Other names: RX 0201, RX-0201, WGI-0201, HC-0201
    Associations

    News

    Trials
    Company:
    Ocuphire Pharma, Zhejiang Haichang Bio-Tech
    Drug class:
    AKT1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    Evaluation of an AKT-1 antisense oligonucleotide in combination with Lenvatinib and Everolimus in Renca-luciferase syngeneic orthotopic murine tumor model (AACR 2023)
    Three drugs combination of Archexin, Lenvatinib and Everolimus, demonstrated superior anti-tumor efficacy compared to the two-drug combination currently used in the clinic. This finding suggests the three-drug combination warrant investigation in the clinical trial in the patients with advanced renal cancer.
    Preclinical • Combination therapy
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1)
    |
    everolimus • Lenvima (lenvatinib) • Archexin (WGI-0201)